Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
ENTERO Vu 24%
Overview
What is ENTERO Vu 24%?
ENTERO VU™ 24% Barium Sulfate Suspension
(24% w/v, 20% w/w) is a barium sulfate suspension for oral administration.
Each 100 mL contains 24 g barium sulfate. Barium sulfate, due to its
high molecular density is opaque to x-rays and, therefore, acts as
a positive contrast agent for radiographic studies. The active ingredient
is barium sulfate and its structural formula is BaSO. Barium sulfate occurs as a fine, white, odorless, tasteless, bulky
powder which is free from grittiness. Its aqueous suspensions are
neutral to litmus. It is practically insoluble in water, solutions
of acids and alkalies, and organic solvents.
Inactive Ingredients:
What does ENTERO Vu 24% look like?
What are the available doses of ENTERO Vu 24%?
Sorry No records found.
What should I talk to my health care provider before I take ENTERO Vu 24%?
Sorry No records found
How should I use ENTERO Vu 24%?
For
radiography of the gastrointestinal tract.
What interacts with ENTERO Vu 24%?
This product should not be used in patients with known gastric or intestinal perforation or hypersensitivity to barium sulfate products.
What are the warnings of ENTERO Vu 24%?
Array
What are the precautions of ENTERO Vu 24%?
General
Diagnostic procedures
which involve the use of radiopaque contrast agents should be carried
out under the direction of personnel with the requisite training and
with a thorough knowledge of the particular procedure to be performed.
A history of bronchial asthma, atopy, as evidenced by hay fever and
eczema, or a previous reaction to a contrast agent, warrant special
attention. Caution should be exercised with the use of radiopaque
media in severely debilitated patients and in those with marked hypertension
or advanced cardiac disease.
Ingestion of this product is not recommended
in patients with a history of food aspiration. If barium studies are
required in these patients or in patients in whom integrity of the
swallowing mechanism is unknown, proceed with caution. If this product
is aspirated into the larynx, further administration should be immediately
discontinued.
After
any barium study of the GI tract, it is important to rehydrate the
patient as quickly as possible to prevent impaction of the bowel by
barium sulfate. To prevent barium sulfate impaction in the bowel,
the use of mild laxatives such as milk of magnesia or lactulose, following
completion of the examination may also be required. These mild laxatives
are recommended on a routine basis and in patients with a history
of constipation unless contraindicated.
Use with caution in patients with complete
or nearly complete obstruction of the GI tract.
Information for Patients
- Inform their physician if they are pregnant.
- Inform their physician if they are allergic to any drugs or food, or if they have had any prior reactions to barium sulfate products or other contrast agents used in x-ray procedures (see ).
- Inform their physician about any other medications they are currently taking.
Before administration of this product patients should be instructed to:
Drug Interactions
The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.
Usage in Pregnancy
Radiation is known to cause harm to the unborn fetus exposed . Therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient.
Nursing Mothers
Barium sulfate products may be used during lactation.
What are the side effects of ENTERO Vu 24%?
Adverse
reactions, such as nausea, vomiting, diarrhea and abdominal cramping,
accompanying the use of barium sulfate formulations are infrequent
and usually mild. Severe reactions (approximately 1 in 1,000,000)
and fatalities (approximately 1 in 10,000,000) have occurred. Procedural
complications are rare, but may include aspiration pneumonitis, barium
sulfate impaction, granuloma formation, intravasation, embolization
and peritonitis following intestinal perforation, vasovagal and syncopal
episodes, and fatalities. It is of the utmost importance to be completely
prepared to treat any such occurrence.
What should I look out for while using ENTERO Vu 24%?
This product
should not be used in patients with known gastric or intestinal perforation
or hypersensitivity to barium sulfate products.
Due to the increased likelihood of allergic reactions
in atopic patients, it is important that a complete history of known
and suspected allergies as well as allergic-like symptoms, e.g., rhinitis,
bronchial asthma, eczema and urticaria, must be obtained prior to
any medical procedure utilizing these products. A mild allergic reaction
would most likely include generalized pruritus, erythema or urticaria
(approximately 1 in 250,000). Such reactions will generally respond
to an antihistamine such as 50 mg of diphenhydramine or its equivalent.
In the rarer, more serious reactions (approximately 1 in 1,000,000)
laryngeal edema, bronchospasm or hypotension could develop. Severe
reactions which may require emergency measures are often characterized
by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea,
agitation, confusion and cyanosis progressing to unconsciousness.
Treatment should be initiated immediately with 0.3 to 0.5 mL of 1:1000
epinephrine subcutaneously. If bronchospasm predominates, 0.25 to
0.50 grams of intravenous aminophylline should be given slowly. Appropriate
vasopressors might be required.
Adrenocorticosteroids, even if given intravenously, exert no significant
effect on the acute allergic reactions for a few hours. The administration
of these agents should not be regarded as emergency measures for the
treatment of allergic reactions.
Apprehensive patients may develop weakness,
pallor, tinnitus, diaphoresis and bradycardia following the administration
of any diagnostic agent. Such reactions are usually non-allergic in
nature and are best treated by having the patient lie flat for an
additional 10 to 30 minutes under observation.
What might happen if I take too much ENTERO Vu 24%?
On rare occasions
following repeated administration, severe stomach cramps, nausea,
vomiting, diarrhea or constipation may occur. These are transitory
in nature and are not considered serious. Symptoms may be treated
according to currently accepted standards of medical care.
How should I store and handle ENTERO Vu 24%?
HandlingReceipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.HandlingReceipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate.ENTERO VU™ 24% is supplied in the following quantity:600 mL jug, Cat. No. L145, NDC 32909-145-06.RxManufactured by E-Z-EM Canada Inc., for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1219-2 ©2006 E-Z-EM, Inc.ENTERO VU™ 24% is supplied in the following quantity:600 mL jug, Cat. No. L145, NDC 32909-145-06.RxManufactured by E-Z-EM Canada Inc., for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1219-2 ©2006 E-Z-EM, Inc.ENTERO VU™ 24% is supplied in the following quantity:600 mL jug, Cat. No. L145, NDC 32909-145-06.RxManufactured by E-Z-EM Canada Inc., for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1219-2 ©2006 E-Z-EM, Inc.ENTERO VU™ 24% is supplied in the following quantity:600 mL jug, Cat. No. L145, NDC 32909-145-06.RxManufactured by E-Z-EM Canada Inc., for E-Z-EM, Inc.a subsidiary of Bracco Diagnostics Inc.Monroe Township, NJ 08831Tel: 1-516-333-8230 1-800 544-4624rev. 05/14 TX1219-2 ©2006 E-Z-EM, Inc.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Barium sulfate,
due to its high molecular density is opaque to x-rays and, therefore,
acts as a positive contrast agent for radiographic studies. Barium
sulfate is biologically inert and, therefore, is not absorbed or metabolized
by the body, and is eliminated unchanged from the body.
Non-Clinical Toxicology
This product should not be used in patients with known gastric or intestinal perforation or hypersensitivity to barium sulfate products.Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g., rhinitis, bronchial asthma, eczema and urticaria, must be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis progressing to unconsciousness. Treatment should be initiated immediately with 0.3 to 0.5 mL of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required.
Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions.
Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.
The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.
Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease.
Ingestion of this product is not recommended in patients with a history of food aspiration. If barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. If this product is aspirated into the larynx, further administration should be immediately discontinued.
After any barium study of the GI tract, it is important to rehydrate the patient as quickly as possible to prevent impaction of the bowel by barium sulfate. To prevent barium sulfate impaction in the bowel, the use of mild laxatives such as milk of magnesia or lactulose, following completion of the examination may also be required. These mild laxatives are recommended on a routine basis and in patients with a history of constipation unless contraindicated.
Use with caution in patients with complete or nearly complete obstruction of the GI tract.
Adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. Severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. Procedural complications are rare, but may include aspiration pneumonitis, barium sulfate impaction, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities. It is of the utmost importance to be completely prepared to treat any such occurrence.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).